Condition: Acute Heart Failure (AHF) · Acute Heart Failure With Reduced Ejection Fraction · Sponsor: University Medical Center Ho Chi Minh City (UMC)
VN-RAPID is an open-label, multicenter, randomized controlled trial evaluating the safety and efficacy of in-hospital initiation and rapid up-titration of four-pillar therapy for hospitalized Asian patients with acute heart failure (AHF) and reduced ejection fraction (HFrEF). The study compares a standardized protocol of intensified treatment (high-intensity care arm) with usual care in patients with elevated NT-proBNP levels who are not on optimal HFrEF medications. The high-intensity care arm involves initiation of all four pillars of HFrEF therapy (RAS inhibitor, beta-blocker, MRA, and SGLT2i) before discharge, followed by a structured 6-week outpatient up-titration process with frequent follow-ups. The study aims for 75% of target doses for RAS inhibitors and beta-blockers, considering the lower blood pressure tendency in Asian populations. Participants will be followed for 180 days to assess clinical outcomes.
This description comes directly from the study's public registry record.
Vu Hoang Vu, Ph.D M.D · +84908431304 · vu.vh@umc.edu.vn
Nam Thanh Hai Phan, M.D · +84937728990 · nam.pth2@umc.edu.vn
Always discuss trial participation with your own doctor first.
| An Giang Heart Hospital | Long Xuyen, An Giang, Vietnam | Not Yet Recruiting |
| Thong Nhat Hospital | Ho Chi Minh City, Ho Chi Minh City, Vietnam | Not Yet Recruiting |
| University Medical Center Ho Chi Minh City | Ho Chi Minh City, Ho Chi Minh City, Vietnam | Recruiting |
| Quang Tri Province Hospital | Đông Hà, Quang Tri, Vietnam | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06595290